AU2005218625A1 - Combination therapy with glatiramer acetate and riluzole - Google Patents
Combination therapy with glatiramer acetate and riluzole Download PDFInfo
- Publication number
- AU2005218625A1 AU2005218625A1 AU2005218625A AU2005218625A AU2005218625A1 AU 2005218625 A1 AU2005218625 A1 AU 2005218625A1 AU 2005218625 A AU2005218625 A AU 2005218625A AU 2005218625 A AU2005218625 A AU 2005218625A AU 2005218625 A1 AU2005218625 A1 AU 2005218625A1
- Authority
- AU
- Australia
- Prior art keywords
- amount
- glatiramer acetate
- amino
- administration
- trifluoromethoxybenzathiazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010072051 Glatiramer Acetate Proteins 0.000 title claims description 238
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 title claims description 224
- 229960003776 glatiramer acetate Drugs 0.000 title claims description 224
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 title description 65
- 229960004181 riluzole Drugs 0.000 title description 58
- 238000002648 combination therapy Methods 0.000 title description 3
- 238000000034 method Methods 0.000 claims description 96
- 201000006417 multiple sclerosis Diseases 0.000 claims description 77
- 239000008194 pharmaceutical composition Substances 0.000 claims description 67
- 230000004112 neuroprotection Effects 0.000 claims description 65
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 53
- 208000024891 symptom Diseases 0.000 claims description 48
- 230000004770 neurodegeneration Effects 0.000 claims description 40
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 37
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 29
- 208000010412 Glaucoma Diseases 0.000 claims description 27
- 229930195712 glutamate Natural products 0.000 claims description 24
- 230000000694 effects Effects 0.000 claims description 23
- 241000700605 Viruses Species 0.000 claims description 22
- 230000000737 periodic effect Effects 0.000 claims description 22
- 231100000331 toxic Toxicity 0.000 claims description 22
- 230000002588 toxic effect Effects 0.000 claims description 22
- 206010021143 Hypoxia Diseases 0.000 claims description 21
- 208000014674 injury Diseases 0.000 claims description 20
- 239000003937 drug carrier Substances 0.000 claims description 19
- 210000003169 central nervous system Anatomy 0.000 claims description 18
- 230000004224 protection Effects 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 15
- 208000016192 Demyelinating disease Diseases 0.000 claims description 15
- 230000006378 damage Effects 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 15
- 206010012305 Demyelination Diseases 0.000 claims description 14
- 208000006011 Stroke Diseases 0.000 claims description 14
- 230000001154 acute effect Effects 0.000 claims description 14
- 208000003435 Optic Neuritis Diseases 0.000 claims description 13
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 13
- YLOCGHYTXIINAI-XKUOMLDTSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 YLOCGHYTXIINAI-XKUOMLDTSA-N 0.000 claims description 12
- 208000020564 Eye injury Diseases 0.000 claims description 12
- 102000010909 Monoamine Oxidase Human genes 0.000 claims description 12
- 108010062431 Monoamine oxidase Proteins 0.000 claims description 12
- 229940042385 glatiramer Drugs 0.000 claims description 12
- 208000030159 metabolic disease Diseases 0.000 claims description 12
- 235000016709 nutrition Nutrition 0.000 claims description 12
- 230000007954 hypoxia Effects 0.000 claims description 11
- 206010002660 Anoxia Diseases 0.000 claims description 10
- 241000976983 Anoxia Species 0.000 claims description 10
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims description 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 10
- 208000027418 Wounds and injury Diseases 0.000 claims description 10
- 230000007953 anoxia Effects 0.000 claims description 10
- 230000001684 chronic effect Effects 0.000 claims description 10
- 208000028867 ischemia Diseases 0.000 claims description 10
- 230000008733 trauma Effects 0.000 claims description 10
- 206010019196 Head injury Diseases 0.000 claims description 9
- 206010028570 Myelopathy Diseases 0.000 claims description 9
- 206010030348 Open-Angle Glaucoma Diseases 0.000 claims description 9
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims description 9
- 230000003210 demyelinating effect Effects 0.000 claims description 9
- 235000012054 meals Nutrition 0.000 claims description 9
- 231100000189 neurotoxic Toxicity 0.000 claims description 9
- 230000002887 neurotoxic effect Effects 0.000 claims description 9
- 230000000472 traumatic effect Effects 0.000 claims description 9
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 8
- 208000016361 genetic disease Diseases 0.000 claims description 8
- 208000009174 transverse myelitis Diseases 0.000 claims description 8
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 claims description 7
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 claims description 7
- 201000011452 Adrenoleukodystrophy Diseases 0.000 claims description 6
- 208000018126 Adrenomyeloneuropathy Diseases 0.000 claims description 6
- 208000006740 Aseptic Meningitis Diseases 0.000 claims description 6
- 206010014612 Encephalitis viral Diseases 0.000 claims description 6
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 claims description 6
- 206010027201 Meningitis aseptic Diseases 0.000 claims description 6
- 201000002498 viral encephalitis Diseases 0.000 claims description 6
- 230000005713 exacerbation Effects 0.000 claims description 4
- 206010028347 Muscle twitching Diseases 0.000 claims description 3
- 238000009825 accumulation Methods 0.000 claims description 3
- 201000010901 lateral sclerosis Diseases 0.000 claims description 3
- 231100000875 loss of motor control Toxicity 0.000 claims description 3
- 208000005264 motor neuron disease Diseases 0.000 claims description 3
- 230000000626 neurodegenerative effect Effects 0.000 claims description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 3
- 230000009747 swallowing Effects 0.000 claims description 3
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 3
- 238000011282 treatment Methods 0.000 description 34
- 241000699670 Mus sp. Species 0.000 description 26
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 24
- 229940079593 drug Drugs 0.000 description 24
- 239000003814 drug Substances 0.000 description 24
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 22
- 101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 22
- 229940049906 glutamate Drugs 0.000 description 21
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 20
- 230000003902 lesion Effects 0.000 description 20
- 229940068196 placebo Drugs 0.000 description 20
- 239000000902 placebo Substances 0.000 description 20
- 238000007920 subcutaneous administration Methods 0.000 description 20
- 229940038717 copaxone Drugs 0.000 description 19
- 239000000203 mixture Substances 0.000 description 19
- -1 for example Substances 0.000 description 15
- 238000002595 magnetic resonance imaging Methods 0.000 description 15
- 239000002671 adjuvant Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical group C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- 229960003638 dopamine Drugs 0.000 description 10
- 230000007717 exclusion Effects 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 9
- 229930006000 Sucrose Natural products 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 238000003304 gavage Methods 0.000 description 9
- 235000011187 glycerol Nutrition 0.000 description 9
- 239000006187 pill Substances 0.000 description 9
- 239000005720 sucrose Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 208000024827 Alzheimer disease Diseases 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 208000000412 Avitaminosis Diseases 0.000 description 8
- 206010021135 Hypovitaminosis Diseases 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 229940072169 rilutek Drugs 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 208000030401 vitamin deficiency disease Diseases 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 208000018737 Parkinson disease Diseases 0.000 description 7
- 229940052764 dopaminergic anti-parkinson drug mao b inhibitors Drugs 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 6
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 6
- 241000206672 Gelidium Species 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 240000007472 Leucaena leucocephala Species 0.000 description 6
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 235000010419 agar Nutrition 0.000 description 6
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 6
- 239000000440 bentonite Substances 0.000 description 6
- 235000012216 bentonite Nutrition 0.000 description 6
- 229910000278 bentonite Inorganic materials 0.000 description 6
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 6
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 6
- 239000001506 calcium phosphate Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000003086 colorant Substances 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 239000000945 filler Substances 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 238000007918 intramuscular administration Methods 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 239000008297 liquid dosage form Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 229960003946 selegiline Drugs 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 210000000278 spinal cord Anatomy 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000000375 suspending agent Substances 0.000 description 6
- 239000006188 syrup Substances 0.000 description 6
- 235000020357 syrup Nutrition 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000000080 wetting agent Substances 0.000 description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
- 235000010443 alginic acid Nutrition 0.000 description 5
- 229920000615 alginic acid Polymers 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 201000002491 encephalomyelitis Diseases 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000004410 intraocular pressure Effects 0.000 description 5
- 230000007787 long-term memory Effects 0.000 description 5
- 210000002161 motor neuron Anatomy 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 5
- 230000006403 short-term memory Effects 0.000 description 5
- 229940001089 sinemet Drugs 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 206010013710 Drug interaction Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 206010067063 Progressive relapsing multiple sclerosis Diseases 0.000 description 4
- 230000001363 autoimmune Effects 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 230000003920 cognitive function Effects 0.000 description 4
- 238000007405 data analysis Methods 0.000 description 4
- 230000036267 drug metabolism Effects 0.000 description 4
- 230000008406 drug-drug interaction Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000002592 gangliocyte Anatomy 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 230000036651 mood Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 4
- 208000002670 vitamin B12 deficiency Diseases 0.000 description 4
- 229940058015 1,3-butylene glycol Drugs 0.000 description 3
- JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 239000005995 Aluminium silicate Substances 0.000 description 3
- 235000003276 Apios tuberosa Nutrition 0.000 description 3
- 244000105624 Arachis hypogaea Species 0.000 description 3
- 235000010777 Arachis hypogaea Nutrition 0.000 description 3
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 3
- 239000004606 Fillers/Extenders Substances 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 3
- 240000003183 Manihot esculenta Species 0.000 description 3
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 102000006386 Myelin Proteins Human genes 0.000 description 3
- 108010083674 Myelin Proteins Proteins 0.000 description 3
- 240000007817 Olea europaea Species 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 235000004443 Ricinus communis Nutrition 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 235000002595 Solanum tuberosum Nutrition 0.000 description 3
- 244000061456 Solanum tuberosum Species 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 3
- 241000710209 Theiler's encephalomyelitis virus Species 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- 206010044565 Tremor Diseases 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 239000002250 absorbent Substances 0.000 description 3
- 230000002745 absorbent Effects 0.000 description 3
- 239000003655 absorption accelerator Substances 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 235000012211 aluminium silicate Nutrition 0.000 description 3
- 230000003376 axonal effect Effects 0.000 description 3
- 229960002903 benzyl benzoate Drugs 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 3
- 235000013539 calcium stearate Nutrition 0.000 description 3
- 239000008116 calcium stearate Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000004927 clay Substances 0.000 description 3
- 238000004040 coloring Methods 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- 235000012343 cottonseed oil Nutrition 0.000 description 3
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 3
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 3
- 229940038472 dicalcium phosphate Drugs 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 230000001804 emulsifying effect Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 229940093499 ethyl acetate Drugs 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 3
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000007913 intrathecal administration Methods 0.000 description 3
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 3
- 238000009533 lab test Methods 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000015654 memory Effects 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 239000004530 micro-emulsion Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000002324 mouth wash Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 210000005012 myelin Anatomy 0.000 description 3
- 230000007971 neurological deficit Effects 0.000 description 3
- 230000002981 neuropathic effect Effects 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 235000010603 pastilles Nutrition 0.000 description 3
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 3
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 235000013772 propylene glycol Nutrition 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 3
- 239000003340 retarding agent Substances 0.000 description 3
- 102220020162 rs397508045 Human genes 0.000 description 3
- 150000004760 silicates Chemical class 0.000 description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 235000010487 tragacanth Nutrition 0.000 description 3
- 239000000196 tragacanth Substances 0.000 description 3
- 229940116362 tragacanth Drugs 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 description 2
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 2
- 102100028116 Amine oxidase [flavin-containing] B Human genes 0.000 description 2
- 101710185931 Amine oxidase [flavin-containing] B Proteins 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- FMGYKKMPNATWHP-UHFFFAOYSA-N Cyperquat Chemical compound C1=C[N+](C)=CC=C1C1=CC=CC=C1 FMGYKKMPNATWHP-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 229910052688 Gadolinium Inorganic materials 0.000 description 2
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 2
- 206010018341 Gliosis Diseases 0.000 description 2
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 2
- 235000019766 L-Lysine Nutrition 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 2
- 206010029350 Neurotoxicity Diseases 0.000 description 2
- 206010069350 Osmotic demyelination syndrome Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 208000037875 astrocytosis Diseases 0.000 description 2
- 230000007341 astrogliosis Effects 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 208000009885 central pontine myelinolysis Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 210000005064 dopaminergic neuron Anatomy 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 201000003104 endogenous depression Diseases 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 2
- 230000004973 motor coordination Effects 0.000 description 2
- 230000007659 motor function Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000007658 neurological function Effects 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000003994 retinal ganglion cell Anatomy 0.000 description 2
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 2
- 229960002646 scopolamine Drugs 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 230000036299 sexual function Effects 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 description 1
- LMGBDZJLZIPJPZ-UHFFFAOYSA-M 1-methyl-4-phenylpyridin-1-ium;chloride Chemical compound [Cl-].C1=C[N+](C)=CC=C1C1=CC=CC=C1 LMGBDZJLZIPJPZ-UHFFFAOYSA-M 0.000 description 1
- NKWZLTFRUPQROQ-UHFFFAOYSA-N 2-(trifluoromethoxy)-1,3-benzothiazole Chemical compound C1=CC=C2SC(OC(F)(F)F)=NC2=C1 NKWZLTFRUPQROQ-UHFFFAOYSA-N 0.000 description 1
- BDOYKFSQFYNPKF-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;sodium Chemical compound [Na].[Na].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O BDOYKFSQFYNPKF-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010009244 Claustrophobia Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- 241001490312 Lithops pseudotruncatella Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 206010027566 Micturition urgency Diseases 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010056677 Nerve degeneration Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 1
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 201000008257 amyotrophic lateral sclerosis type 1 Diseases 0.000 description 1
- 210000002226 anterior horn cell Anatomy 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical class C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000004002 dopaminergic cell Anatomy 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000019995 familial amyotrophic lateral sclerosis Diseases 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 230000004886 head movement Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000009114 investigational therapy Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000008986 metabolic interaction Effects 0.000 description 1
- 230000006676 mitochondrial damage Effects 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 238000010984 neurological examination Methods 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- WLGDAKIJYPIYLR-UHFFFAOYSA-N octane-1-sulfonic acid Chemical compound CCCCCCCCS(O)(=O)=O WLGDAKIJYPIYLR-UHFFFAOYSA-N 0.000 description 1
- 210000003977 optic chiasm Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000028527 righting reflex Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 230000006886 spatial memory Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000019929 sporadic amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000012301 transgenic model Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000031836 visual learning Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Psychology (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54997404P | 2004-03-03 | 2004-03-03 | |
| US54997604P | 2004-03-03 | 2004-03-03 | |
| US54997504P | 2004-03-03 | 2004-03-03 | |
| US60/549,975 | 2004-03-03 | ||
| US60/549,976 | 2004-03-03 | ||
| US60/549,974 | 2004-03-03 | ||
| PCT/US2005/007072 WO2005084377A2 (en) | 2004-03-03 | 2005-03-03 | Combination therapy with glatiramer acetate and riluzole |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2005218625A1 true AU2005218625A1 (en) | 2005-09-15 |
Family
ID=34923270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2005218625A Abandoned AU2005218625A1 (en) | 2004-03-03 | 2005-03-03 | Combination therapy with glatiramer acetate and riluzole |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20070244056A1 (enExample) |
| EP (1) | EP1778286A4 (enExample) |
| JP (1) | JP2007535498A (enExample) |
| AU (1) | AU2005218625A1 (enExample) |
| CA (1) | CA2558380A1 (enExample) |
| IL (1) | IL177845A0 (enExample) |
| WO (1) | WO2005084377A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1797109T3 (en) * | 2004-09-09 | 2016-04-11 | Yeda Res & Dev | MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof |
| JP2008528589A (ja) * | 2005-02-02 | 2008-07-31 | テバ ファーマシューティカル インダストリーズ リミティド | 水素化分解を用いてポリペプチド混合物を作成する方法 |
| US8491890B2 (en) * | 2008-07-09 | 2013-07-23 | Board Of Regents Of The University Of Nebraska | Methods and compositions for inhibiting diseases of the central nervous system |
| EP2228054A1 (en) | 2009-03-13 | 2010-09-15 | ITALFARMACO S.p.A. | Riluzole aqueous suspensions |
| KR20160038057A (ko) | 2009-08-20 | 2016-04-06 | 에다 리서치 앤드 디벨럽먼트 컴퍼니 리미티드 | 글라티라머 아세테이트를 포함하는 약제 |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| EP2627669B1 (en) | 2010-10-11 | 2016-08-17 | Teva Pharmaceutical Industries Ltd. | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
| EP2736335A4 (en) * | 2011-07-28 | 2015-01-07 | Teva Pharma | TREATMENT OF MULTIPLE SCLEROSIS USING A COMBINATION OF LAQUINIMOD AND GLATIRAMERATE ACETATE |
| US8815511B2 (en) | 2011-10-10 | 2014-08-26 | Teva Pharmaceutical Industries, Ltd. | Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate |
| TW201420111A (zh) | 2012-10-10 | 2014-06-01 | Teva Pharma | 對格拉默醋酸鹽（ｇｌａｔｉｒａｍｅｒ ａｃｅｔａｔｅ）之臨床反應具預測性之生物標記 |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| KR102580378B1 (ko) * | 2014-11-21 | 2023-09-19 | 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. | 릴루졸의 설하 제제 |
| JP6827924B2 (ja) | 2014-11-26 | 2021-02-10 | メディシノバ・インコーポレイテッドＭｅｄｉｃｉＮｏｖａ， Ｉｎｃ． | イブジラスト及びリルゾールの組み合わせを含む医薬および組成物 |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| SMT202500136T1 (it) | 2016-08-31 | 2025-05-12 | Mapi Pharma Ltd | Sistemi a deposito comprendenti glatiramer acetato |
| US11167003B2 (en) | 2017-03-26 | 2021-11-09 | Mapi Pharma Ltd. | Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5800808A (en) * | 1994-05-24 | 1998-09-01 | Veda Research And Development Co., Ltd. | Copolymer-1 improvements in compositions of copolymers |
| US6214791B1 (en) * | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| ES2527760T3 (es) * | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| WO2000005250A1 (en) * | 1998-07-23 | 2000-02-03 | Yeda Research And Development Co., Ltd | Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides |
| US6514938B1 (en) * | 1998-09-25 | 2003-02-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| US6800287B2 (en) * | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| DE60017733T2 (de) * | 1999-06-04 | 2006-01-12 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | Verwendung von riluzol zur behandlung multipler sklerose |
| US6872739B1 (en) * | 1999-06-04 | 2005-03-29 | Vereniging Voor Christelijk Wetenshappelikjk Onderwijs | Use of riluzole for the treatment of multiple sclerosis |
| EP1248643B1 (en) * | 2000-01-20 | 2005-08-17 | YEDA RESEARCH AND DEVELOPMENT Co. LTD. | The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy |
| US7022663B2 (en) * | 2000-02-18 | 2006-04-04 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
| US20020077278A1 (en) * | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| WO2002076503A1 (en) * | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| CN1308683C (zh) * | 2001-12-04 | 2007-04-04 | 特瓦制药工业有限公司 | 测量醋酸格拉默功效的方法 |
| EP1429800B1 (en) * | 2001-12-06 | 2009-02-11 | Yeda Research And Development Co., Ltd. | Vaccine and use thereof for treatment of amyotrophic lateral sclerosis |
| JP3704711B2 (ja) * | 2003-06-20 | 2005-10-12 | 船井電機株式会社 | 液晶テレビジョン用台座 |
| NZ546379A (en) * | 2003-10-31 | 2010-04-30 | Teva Pharma | Nanoparticles for drug delivery |
| DK1799703T3 (da) * | 2004-09-09 | 2010-04-19 | Teva Pharma | Fremgangsmåde til fremstilling af blandinger af polypeptider ved hjælp af oprenset hydrogenbromid |
| DK1797109T3 (en) * | 2004-09-09 | 2016-04-11 | Yeda Res & Dev | MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof |
| JP2008528589A (ja) * | 2005-02-02 | 2008-07-31 | テバ ファーマシューティカル インダストリーズ リミティド | 水素化分解を用いてポリペプチド混合物を作成する方法 |
-
2005
- 2005-03-03 WO PCT/US2005/007072 patent/WO2005084377A2/en not_active Ceased
- 2005-03-03 AU AU2005218625A patent/AU2005218625A1/en not_active Abandoned
- 2005-03-03 JP JP2007502006A patent/JP2007535498A/ja not_active Withdrawn
- 2005-03-03 US US10/591,195 patent/US20070244056A1/en not_active Abandoned
- 2005-03-03 CA CA002558380A patent/CA2558380A1/en not_active Abandoned
- 2005-03-03 EP EP05724586A patent/EP1778286A4/en not_active Withdrawn
-
2006
- 2006-08-31 IL IL177845A patent/IL177845A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007535498A (ja) | 2007-12-06 |
| US20070244056A1 (en) | 2007-10-18 |
| EP1778286A4 (en) | 2009-04-08 |
| WO2005084377A2 (en) | 2005-09-15 |
| IL177845A0 (en) | 2006-12-31 |
| EP1778286A2 (en) | 2007-05-02 |
| WO2005084377A3 (en) | 2008-01-31 |
| CA2558380A1 (en) | 2005-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20070244056A1 (en) | Combination Therapy With Glatiramer Acetate and Riluzole | |
| US7968511B2 (en) | Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis | |
| US20100167983A1 (en) | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis | |
| US20090048181A1 (en) | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis | |
| EP0866691B1 (en) | Sublingual and buccal administration of selegiline | |
| EP1848415B1 (en) | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis | |
| US20070037740A1 (en) | Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis | |
| CN101227898A (zh) | 使用醋酸格拉默和利鲁唑的组合治疗 | |
| Babington et al. | The influence of cinanserin and selected pharmacologic agents on experimental allergic encephalomyelitis (EAE) | |
| JP7121859B2 (ja) | 安息香酸塩または安息香酸誘導体を含む、抗ｎ－メチル－ｄ－アスパラギン酸受容体脳炎を予防または治療するための医薬組成物 | |
| US20070238711A1 (en) | Combination Therapy with Glatiramer Acetate and Minocycline for the Treatment of Multiple Sclerosis | |
| SOLEIMANI et al. | Risk factor profiles of adverse neuromotor outcome in infants | |
| WO2004078145A2 (en) | Combination therapy with glatiramer acetate and simvastatin for the treatment of multiple sclerosis | |
| James | Schizophrenia as a genetic morphism |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |